GLP-1 Medications and Mental Health: Mood, Anxiety, and Depression

The connection people are talking about

GLP-1 medications affect the brain — not just the gut and pancreas. GLP-1 receptors exist throughout the central nervous system, including areas involved in mood regulation and reward processing. This has led to intense interest — and some concern — about how these medications might affect mental health. Patient experiences range from reports of improved mood and reduced anxiety to, in rare cases, worsening depression. Here is what the clinical evidence actually shows.

What the clinical trial data says

Large-scale clinical trials for both semaglutide and tirzepatide did not find increased rates of depression, anxiety, or suicidal ideation compared to placebo. In the STEP trials, rates of depression were low and did not differ meaningfully between semaglutide and placebo groups. The SURMOUNT trials showed similar findings for tirzepatide. However, clinical trials exclude people with significant pre-existing mental health conditions, so the data applies primarily to people without active, severe depression or anxiety. The FDA and EMA have conducted formal reviews and have not established a causal link between GLP-1 medications and suicidal thoughts, though monitoring continues.

The food noise phenomenon — a positive effect

Many people on GLP-1 medications describe a profound reduction in what they call food noise — constant, intrusive thoughts about food, eating, and weight. This phenomenon represents a significant mental health benefit for many patients. People describe experiencing mental quiet for the first time in years, reduced anxiety around food, and improved overall psychological wellbeing. This effect appears to be mediated by GLP-1 receptor activity in brain regions involved in reward and motivation.

Who should be cautious

People with a history of major depressive disorder or suicidal ideation should discuss GLP-1 treatment thoroughly with their provider. Those in active mental health treatment should ensure their mental health provider is aware they are starting GLP-1. As with any new medication, monitoring for mood changes during the first weeks of treatment is advisable.